Warning: trigger_error(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: Table './themoney_2011new/watchdog' is marked as crashed and last (automatic?) repair failed query: INSERT INTO watchdog (uid, type, message, variables, severity, link, location, referer, hostname, timestamp) VALUES (0, 'php', '%message in %file on line %line.', 'a:4:{s:6:\"%error\";s:14:\"strict warning\";s:8:\"%message\";s:62:\"Non-static method view::load() should not be called statically\";s:5:\"%file\";s:63:\"/home/themoney/public_html/sites/all/modules/views/views.module\";s:5:\"%line\";i:906;}', 3, '', 'http://www.themoneytimes.com/taxonomy/term/10362/all/feed', '', '54.144.83.141', 1455422042) in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: trigger_error(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: Table './themoney_2011new/watchdog' is marked as crashed and last (automatic?) repair failed query: INSERT INTO watchdog (uid, type, message, variables, severity, link, location, referer, hostname, timestamp) VALUES (0, 'php', '%message in %file on line %line.', 'a:4:{s:6:\"%error\";s:14:\"strict warning\";s:8:\"%message\";s:109:\"Declaration of views_handler_argument::init() should be compatible with views_handler::init(&$view, $options)\";s:5:\"%file\";s:86:\"/home/themoney/public_html/sites/all/modules/views/handlers/views_handler_argument.inc\";s:5:\"%line\";i:744;}', 3, '', 'http://www.themoneytimes.com/taxonomy/term/10362/all/feed', '', '54.144.83.141', 1455422042) in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: trigger_error(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: Table './themoney_2011new/watchdog' is marked as crashed and last (automatic?) repair failed query: INSERT INTO watchdog (uid, type, message, variables, severity, link, location, referer, hostname, timestamp) VALUES (0, 'php', '%message in %file on line %line.', 'a:4:{s:6:\"%error\";s:14:\"strict warning\";s:8:\"%message\";s:134:\"Declaration of views_handler_filter::options_validate() should be compatible with views_handler::options_validate($form, &$form_state)\";s:5:\"%file\";s:84:\"/home/themoney/public_html/sites/all/modules/views/handlers/views_handler_filter.inc\";s:5:\"%line\";i:607;}', 3, '', 'http://www.themoneytimes.com/taxonomy/term/10362/all/feed', '', '54.144.83.141', 1455422042) in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: trigger_error(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: Table './themoney_2011new/watchdog' is marked as crashed and last (automatic?) repair failed query: INSERT INTO watchdog (uid, type, message, variables, severity, link, location, referer, hostname, timestamp) VALUES (0, 'php', '%message in %file on line %line.', 'a:4:{s:6:\"%error\";s:14:\"strict warning\";s:8:\"%message\";s:130:\"Declaration of views_handler_filter::options_submit() should be compatible with views_handler::options_submit($form, &$form_state)\";s:5:\"%file\";s:84:\"/home/themoney/public_html/sites/all/modules/views/handlers/views_handler_filter.inc\";s:5:\"%line\";i:607;}', 3, '', 'http://www.themoneytimes.com/taxonomy/term/10362/all/feed', '', '54.144.83.141', 1455422042) in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: trigger_error(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: Table './themoney_2011new/watchdog' is marked as crashed and last (automatic?) repair failed query: INSERT INTO watchdog (uid, type, message, variables, severity, link, location, referer, hostname, timestamp) VALUES (0, 'php', '%message in %file on line %line.', 'a:4:{s:6:\"%error\";s:14:\"strict warning\";s:8:\"%message\";s:148:\"Declaration of views_handler_filter_node_status::operator_form() should be compatible with views_handler_filter::operator_form(&$form, &$form_state)\";s:5:\"%file\";s:100:\"/home/themoney/public_html/sites/all/modules/views/modules/node/views_handler_filter_node_status.inc\";s:5:\"%line\";i:13;}', 3, '', 'http://www.themoneytimes.com/taxonomy/term/10362/all/feed', '', '54.144.83.141', 1455422042) in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: trigger_error(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: Table './themoney_2011new/watchdog' is marked as crashed and last (automatic?) repair failed query: INSERT INTO watchdog (uid, type, message, variables, severity, link, location, referer, hostname, timestamp) VALUES (0, 'php', '%message in %file on line %line.', 'a:4:{s:6:\"%error\";s:14:\"strict warning\";s:8:\"%message\";s:62:\"Non-static method view::load() should not be called statically\";s:5:\"%file\";s:63:\"/home/themoney/public_html/sites/all/modules/views/views.module\";s:5:\"%line\";i:906;}', 3, '', 'http://www.themoneytimes.com/taxonomy/term/10362/all/feed', '', '54.144.83.141', 1455422042) in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: trigger_error(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: Table './themoney_2011new/watchdog' is marked as crashed and last (automatic?) repair failed query: INSERT INTO watchdog (uid, type, message, variables, severity, link, location, referer, hostname, timestamp) VALUES (0, 'php', '%message in %file on line %line.', 'a:4:{s:6:\"%error\";s:14:\"strict warning\";s:8:\"%message\";s:130:\"Declaration of views_plugin_row::options_validate() should be compatible with views_plugin::options_validate(&$form, &$form_state)\";s:5:\"%file\";s:79:\"/home/themoney/public_html/sites/all/modules/views/plugins/views_plugin_row.inc\";s:5:\"%line\";i:134;}', 3, '', 'http://www.themoneytimes.com/taxonomy/term/10362/all/feed', '', '54.144.83.141', 1455422042) in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: trigger_error(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: Table './themoney_2011new/watchdog' is marked as crashed and last (automatic?) repair failed query: INSERT INTO watchdog (uid, type, message, variables, severity, link, location, referer, hostname, timestamp) VALUES (0, 'php', '%message in %file on line %line.', 'a:4:{s:6:\"%error\";s:14:\"strict warning\";s:8:\"%message\";s:126:\"Declaration of views_plugin_row::options_submit() should be compatible with views_plugin::options_submit(&$form, &$form_state)\";s:5:\"%file\";s:79:\"/home/themoney/public_html/sites/all/modules/views/plugins/views_plugin_row.inc\";s:5:\"%line\";i:134;}', 3, '', 'http://www.themoneytimes.com/taxonomy/term/10362/all/feed', '', '54.144.83.141', 1455422042) in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: trigger_error(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: Table './themoney_2011new/watchdog' is marked as crashed and last (automatic?) repair failed query: INSERT INTO watchdog (uid, type, message, variables, severity, link, location, referer, hostname, timestamp) VALUES (0, 'php', '%message in %file on line %line.', 'a:4:{s:6:\"%error\";s:7:\"warning\";s:8:\"%message\";s:137:\"Cannot modify header information - headers already sent by (output started at /home/themoney/public_html/includes/database.mysql.inc:135)\";s:5:\"%file\";s:46:\"/home/themoney/public_html/includes/common.inc\";s:5:\"%line\";i:153;}', 3, '', 'http://www.themoneytimes.com/taxonomy/term/10362/all/feed', '', '54.144.83.141', 1455422043) in /home/themoney/public_html/includes/database.mysql.inc on line 135
approval http://www.themoneytimes.com/taxonomy/term/10362/all/feed en FDA clears vandetanib for treatment of rare thyroid cancer http://www.themoneytimes.com/featured/20110407/fda-clears-vandetanib-treatment-rare-thyroid-cancer-id-101701709873.html <div class="field field-type-text field-field-teaser"> <div class="field-items"> <div class="field-item odd"> <p>British pharmaceutical giant AstraZeneca Plc got the green signal from the U.S. Food and Drug Administration (FDA) Wednesday, for its new drug vandetanib for the treatment of a rare form of thyroid cancer.</p> </div> </div> </div> <div class="field field-type-filefield field-field-image"> <div class="field-items"> <div class="field-item odd"> <img src="http://www.themoneytimes.com/files/imagecache/picturethumb/1294709424-29.jpg" alt="" title="" class="imagecache imagecache-picturethumb imagecache-default imagecache-picturethumb_default" width="180" height="125" /> </div> </div> </div> <p>Vandetanib is the only prescription drug approved by the health regulators to help tackle the inoperable, difficult to treat medullary thyroid cancer that can be fatal if it metastasizes to other parts of the body.</p> <p>Vandetanib works by starving the malignant cells of oxygen and nutrients they need to survive and flourish. </p> <p>The drug blocks the process of new blood vessel growth that plays a vital role in cancer development.</p> <div class="field field-type-text field-field-imagecaption"> <div class="field-items"> <div class="field-item odd"> <p>Vandetanib works by starving the malignant cells of oxygen and nutrients they need to survive and flourish. The drug blocks the process of new blood vessel growth that plays a vital role in cancer development.</p> </div> </div> </div> <p><a href="http://www.themoneytimes.com/featured/20110407/fda-clears-vandetanib-treatment-rare-thyroid-cancer-id-101701709873.html" target="_blank">read more</a></p> approval British pharmaceutical giant AstraZeneca Plc Healthcare randomized international study rare form of thyroid cancer safety and efficacy assessed single sold under restricted distribution program Top Story U.S. Food and Drug Administration (FDA) new drug vandetanib United States Thu, 07 Apr 2011 09:31:59 +0000 Neka Sehgal 1701709873 at http://www.themoneytimes.com FDA approves Benlysta, first drug to treat lupus in 56 years http://www.themoneytimes.com/featured/20110310/fda-approves-benlysta-first-drug-treat-lupus-56-years-id-101701709608.html <div class="field field-type-text field-field-teaser"> <div class="field-items"> <div class="field-item odd"> <p>The Food and Drug Administration (FDA) has cleared Benlysta, the first new drug to treat lupus in 56 years, designed to relieve flare-ups and pain in certain patients who are receiving standard therapy for the deadly autoimmune disease.</p> </div> </div> </div> <div class="field field-type-filefield field-field-image"> <div class="field-items"> <div class="field-item odd"> <img src="http://www.themoneytimes.com/files/imagecache/picturethumb/Lupus_facial_rash_330px_Wikipedia.jpg" alt="" title="" class="imagecache imagecache-picturethumb imagecache-default imagecache-picturethumb_default" width="180" height="153" /> </div> </div> </div> <p>Benlysta, developed by Human Genome Sciences in collaboration with GlaxoSmithKline (GSK), helps combat lupus, a disease that causes the immune system to attack the body’s own tissue and organs.</p> <p>H. Thomas Watkins, President and Chief Executive Officer, Human Genome Sciences stated, “We and GSK are honored to have the opportunity, with the approval of FDA, to bring Benlysta forward in the United States as the first new drug for systemic lupus in more than 50 years.</p> <div class="field field-type-text field-field-imagecaption"> <div class="field-items"> <div class="field-item odd"> <p>Currently, steroids and immunosuppressants therapies are used to treat inflammation, pain and tissue damage, the typical symptoms of lupus.</p> </div> </div> </div> <p><a href="http://www.themoneytimes.com/featured/20110310/fda-approves-benlysta-first-drug-treat-lupus-56-years-id-101701709608.html" target="_blank">read more</a></p> an intravenous drug approval autoantibodies Benlysta bodily protein known as the B-lymphocyte stimulator clinical trails cripples the immune system to attack the body’s own tissue and organs deadly autoimmune disease Health Human Genome Sciences in collaboration with GlaxoSmithKline (GSK) Lupus The Food and Drug Administration (FDA) Top Story United States Thu, 10 Mar 2011 09:48:44 +0000 Neka Sehgal 1701709608 at http://www.themoneytimes.com Chilli cakes, chocolates to burn off calories http://www.themoneytimes.com/featured/20110308/chilli-cakes-chocolates-burn-calories-id-101701709588.html <div class="field field-type-text field-field-teaser"> <div class="field-items"> <div class="field-item odd"> <p>Ever imagined losing weight through chocolates and cakes? Well, mouth-watering desserts to help people shed flab is soon going to become a reality.</p> </div> </div> </div> <div class="field field-type-filefield field-field-image"> <div class="field-items"> <div class="field-item odd"> <img src="http://www.themoneytimes.com/files/imagecache/picturethumb/chilli-chocolate_orange_birthday_cake_by_sam_stern.jpg" alt="" title="" class="imagecache imagecache-picturethumb imagecache-default imagecache-picturethumb_default" width="180" height="151" /> </div> </div> </div> <p>Ajinomoto, a Japanese food company, has announced plans to introduce food stuffs that will lead to weight loss.</p> <p>The manufacturers claim that they have found an extract of chilli which when added to desserts and pudding can burn off calories.</p> <blockquote><p>"Most weight management aids focus on caloric intake. Capsinoids are unique in targeting the other side of the equation, the caloric output. DHC is not positioned as a 'magic bullet,' rather, it should be used as one piece of the overall weight management equation.”--Ajinomoto spokeswoman Naoko Obara </p></blockquote> <div class="field field-type-text field-field-imagecaption"> <div class="field-items"> <div class="field-item odd"> <p>The manufacturers claim that they have found an extract of chilli peppers which when added to desserts and pudding can burn off calories.</p> </div> </div> </div> <p><a href="http://www.themoneytimes.com/featured/20110308/chilli-cakes-chocolates-burn-calories-id-101701709588.html" target="_blank">read more</a></p> Ajinomoto approval Britain's Food Standards Agency burn off calories calories Chemical chilli desserts DHC European Commission food products foods Health Top Story United States weight loss Tue, 08 Mar 2011 06:51:54 +0000 Jaspreet Virk 1701709588 at http://www.themoneytimes.com FDA grants hearing to Genentech over breast cancer drug http://www.themoneytimes.com/featured/20110225/fda-grants-hearing-genentech-over-breast-cancer-drug-id-101701709508.html <div class="field field-type-text field-field-teaser"> <div class="field-items"> <div class="field-item odd"> <p>Genentech, a Roche subsidiary, has been informed through a letter by the Food and Drug Administration (FDA) that the federal agency is ready to give another chance to the company to argue in favour of of ‘Avastin’ a drug for breast cancer.</p> </div> </div> </div> <div class="field field-type-filefield field-field-image"> <div class="field-items"> <div class="field-item odd"> <img src="http://www.themoneytimes.com/files/imagecache/picturethumb/genentech-Avastin.png" alt="" title="" class="imagecache imagecache-picturethumb imagecache-default imagecache-picturethumb_default" width="180" height="135" /> </div> </div> </div> <p>The FDA letter sent to the lawyers of the company on Wednesday allows two day s of public hearing to the company.</p> <p><strong>Genentech gets another chance</strong><br /> Genentech has been fighting against the decision of the FDA since Dec.16 last year, when the agency announced its intention to revoke its approval to Avastin for breast cancer. </p> <p>Almost at the same time European officials had announced that they will allow the use of the drug only when combined with one type of chemotherapy.</p> <div class="field field-type-text field-field-imagecaption"> <div class="field-items"> <div class="field-item odd"> <p>When Genentech requested for a public hearing it has claimed that the Oncologic Drugs Advisory Committee of the FDA did not have enough cancer specialists.</p> </div> </div> </div> <p><a href="http://www.themoneytimes.com/featured/20110225/fda-grants-hearing-genentech-over-breast-cancer-drug-id-101701709508.html" target="_blank">read more</a></p> approval Avastin breast cancer drug FDA Genentech Health Public hearing side effects Top Story United States Fri, 25 Feb 2011 11:49:33 +0000 Anter Prakash Singh 1701709508 at http://www.themoneytimes.com FDA gives nod to first 3-D mammography imaging system http://www.themoneytimes.com/featured/20110212/fda-gives-nod-first-3d-mammography-imaging-system-id-101701709387.html <div class="field field-type-text field-field-teaser"> <div class="field-items"> <div class="field-item odd"> <p>On Friday, the Food and Drug Administration (FDA) granted approval to Selenia Dimensions digital breast tomosynthesis system marketed by Hologic Inc. of Bedford, Mass., the first such device to be sold in the nation that will produce three-dimensional images of the breast for cancer screening and diagnosis.</p> </div> </div> </div> <div class="field field-type-filefield field-field-image"> <div class="field-items"> <div class="field-item odd"> <img src="http://www.themoneytimes.com/files/imagecache/picturethumb/Getty_H_102910_OlderWomanMammogram.jpg" alt="" title="" class="imagecache imagecache-picturethumb imagecache-default imagecache-picturethumb_default" width="180" height="122" /> </div> </div> </div> <p>According to Hologic, the existing 2-D digital mammography causes about 10 percent of women to undergo additional screening after an initial test, only to detect apparent abnormalities in the breast as benign.</p> <p>However, the new 3-D breast scanning technology is superior because it can accurately detect cancerous masses hidden by overlying breast tissue.</p> <div class="field field-type-text field-field-imagecaption"> <div class="field-items"> <div class="field-item odd"> <p>The new 3-D breast scanning technology is superior because it can accurately detect cancerous masses hidden by overlying breast tissue.</p> </div> </div> </div> <p><a href="http://www.themoneytimes.com/featured/20110212/fda-gives-nod-first-3d-mammography-imaging-system-id-101701709387.html" target="_blank">read more</a></p> approval basis of 2 studies combined 2D and 3D images cuts the need for additional screening delivers more radiation FDA Health mammography imaging marketed by Hologic Inc. of Bedford Mass. more accurate more accurate detect and diagnose breast cancer The Selenia Dimensions System United States Sat, 12 Feb 2011 09:58:33 +0000 Neka Sehgal 1701709387 at http://www.themoneytimes.com FDA approves Makena for reducing risk of preterm birth http://www.themoneytimes.com/featured/20110205/fda-approves-makena-reducing-risk-preterm-birth-id-101701709327.html <div class="field field-type-text field-field-teaser"> <div class="field-items"> <div class="field-item odd"> <p>Finally a drug option to prevent preterm births. Researchers claim that it can help at-risk pregnant women reach full term.</p> </div> </div> </div> <div class="field field-type-filefield field-field-image"> <div class="field-items"> <div class="field-item odd"> <img src="http://www.themoneytimes.com/files/imagecache/picturethumb/Diabetes-and-a-hale-pregnancy.jpg" alt="" title="" class="imagecache imagecache-picturethumb imagecache-default imagecache-picturethumb_default" width="180" height="142" /> </div> </div> </div> <p>The Food and Drug Administration (FDA) announced Friday that it has approved Makena, a progesterone injection that promises to reduce the risk of premature birth in women who have already had a preterm delivery before 37 weeks of pregnancy.</p> <p>Makena, has been given an expedited approval by the FDA, which means the manufacturer is required to conduct additional studies to ascertain that there are no developmental problems typically linked with premature births. </p> <div class="field field-type-text field-field-imagecaption"> <div class="field-items"> <div class="field-item odd"> <p>Makena is administered by injection. The shot is given by a health care provider once a week into the hip of the mom-to-be. </p> </div> </div> </div> <p><a href="http://www.themoneytimes.com/featured/20110205/fda-approves-makena-reducing-risk-preterm-birth-id-101701709327.html" target="_blank">read more</a></p> http://www.themoneytimes.com/featured/20110205/fda-approves-makena-reducing-risk-preterm-birth-id-101701709327.html#comments approval FDA first drug to reduce risk of premature deliver Health Makena no major adverse effects progesterone injection safety and efficacy assessed Top Story United States Sat, 05 Feb 2011 13:39:17 +0000 Neka Sehgal 1701709327 at http://www.themoneytimes.com 2010 FDA Approvals and a Look Ahead http://www.themoneytimes.com/featured/20110101/2010-fda-approvals-and-look-ahead-id-101701708998.html <div class="field field-type-text field-field-teaser"> <div class="field-items"> <div class="field-item odd"> <p>&nbsp;Anyone who's kept an eye on the drugmakers this year won't be surprised by this statistic: The Food and Drug Administration approved fewer drugs this year than it has since 2007. According to the&nbsp;<em style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; font-family: inherit; font-size: 14px; font-style: italic; font-weight: inherit; ">Wall Street Journal</em>, which took the time to add them all up, the FDA only approved 21 drugs this year, compared with 25 in 2009 and 24 in 2008.</p> <div style="font-size: 14px; color: rgb(34, 34, 34); font-family: Arial, Helvetica, sans-serif; line-height: 22px; ">&nbsp;</div> </div> </div> </div> <p>&nbsp;Dwelling on the past isn't usually all that useful for investors; the markets are forward-looking after all. But a little review of recent drug approvals and rejections is useful to see what the future holds for drugmakers in 2011 and beyond.</p> <div class="field field-type-filefield field-field-image"> <div class="field-items"> <div class="field-item odd"> <img src="http://www.themoneytimes.com/files/imagecache/picturethumb/Dendreon%20logo_4.jpg" alt="" title="" class="imagecache imagecache-picturethumb imagecache-default imagecache-picturethumb_default" width="180" height="102" /> </div> </div> </div> <p><a href="http://www.themoneytimes.com/featured/20110101/2010-fda-approvals-and-look-ahead-id-101701708998.html" target="_blank">read more</a></p> http://www.themoneytimes.com/featured/20110101/2010-fda-approvals-and-look-ahead-id-101701708998.html#comments approval approved Arena Pharmaceuticals clinical Dendreon drugmakers GlaxoSmithKline MannKind Markets United States Sat, 01 Jan 2011 02:20:36 +0000 Brian Orelli 1701708998 at http://www.themoneytimes.com FDA okays Gardasil for anal cancer prevention http://www.themoneytimes.com/featured/20101226/fda-okays-gardasil-anal-cancer-prevention-id-10145550.html <div class="field field-type-text field-field-teaser"> <div class="field-items"> <div class="field-item odd"> <p>In what can be termed as significant step in the prevention of anal cancer, the U.S. Food and Drug Administration (FDA) has given regulatory approval to Gardasil, a human papillomavirus vaccine.</p> </div> </div> </div> <div class="field field-type-filefield field-field-image"> <div class="field-items"> <div class="field-item odd"> <img src="http://www.themoneytimes.com/files/imagecache/picturethumb/vaccine-bottle-literature.jpg" alt="" title="" class="imagecache imagecache-picturethumb imagecache-default imagecache-picturethumb_default" width="180" height="135" /> </div> </div> </div> <p>Gardasil which has already got the FDA nod to prevent cervical, vulvar and vaginal cancer will now also be used for anal cancer and associated precancerous lesions caused by human papillomavirus (HPV) types 6, 11, 16, and 18.</p> <p>The vaccine Gardasil, which is manufactured by Merck and Co. Inc. will cover patients in the ages 9 to 26 years.</p> <div class="field field-type-text field-field-imagecaption"> <div class="field-items"> <div class="field-item odd"> <p>Though the vaccine is effective in preventing anal cancer, the FDA has clarified that Gardasil will not “prevent the development of anal precancerous lesions” that are already present at the time of vaccination.</p> </div> </div> </div> <p><a href="http://www.themoneytimes.com/featured/20101226/fda-okays-gardasil-anal-cancer-prevention-id-10145550.html" target="_blank">read more</a></p> http://www.themoneytimes.com/featured/20101226/fda-okays-gardasil-anal-cancer-prevention-id-10145550.html#comments Anal cancer approval diagnosed disease FDA Food and Drug Administration Health HPV Merck and Co. Inc. Top Story United States vaccine Sun, 26 Dec 2010 06:20:56 +0000 Jaspreet Virk 145550 at http://www.themoneytimes.com Our Drug Is Better Than Your Drug http://www.themoneytimes.com/featured/20101222/our-drug-better-your-drug-id-10145342.html <div class="field field-type-text field-field-teaser"> <div class="field-items"> <div class="field-item odd"> <p><span style="border-collapse: separate; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;" class="Apple-style-span"><span style="color: rgb(34, 34, 34); font-family: Arial,Helvetica,sans-serif; font-size: 14px; line-height: 22px; text-align: left;" class="Apple-style-span"><em style="border-width: 0px; margin: 0px; padding: 0px; font-family: inherit; font-size: 14px; font-style: italic; font-weight: inherit;">"I am highly confident that at the end of the day, when all the cards are on the table, we will be, not only the JAK1 and 2 inhibitor that is two to three years ahead of any potential competition, but that we have the best compound."<br /></em>-- Paul Friedman, President and CEO of<span class="Apple-converted-space">&nbsp;</span><strong style="border-width: 0px; margin: 0px; padding: 0px; font-family: inherit; font-size: 14px; font-style: inherit; font-weight: bold;">Incyte</strong><span class="Apple-converted-space">&nbsp;</span><span style="border-width: 0px; margin: 0px; padding: 0px; font-family: inherit; font-size: 14px; font-style: inherit; font-weight: inherit;" class="ticker">(Nasdaq:<span class="Apple-converted-space">&nbsp;</span>INCY)</span>.</span></span></p> </div> </div> </div> <p><span style="border-collapse: separate; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;" class="Apple-style-span"><span style="color: rgb(34, 34, 34); font-family: Arial,Helvetica,sans-serif; font-size: 14px; line-height: 22px; text-align: left;" class="Apple-style-span"><p style="border-width: 0px; margin: 11px 0px; padding: 0px; font-family: Arial,Helvetica,sa</p> </p></span></span></p><div class="field field-type-filefield field-field-image"> <div class="field-items"> <div class="field-item odd"> <img src="http://www.themoneytimes.com/files/imagecache/picturethumb/Novartis_1.jpg" alt="" title="" class="imagecache imagecache-picturethumb imagecache-default imagecache-picturethumb_default" width="180" height="44" /> </div> </div> </div> <p><a href="http://www.themoneytimes.com/featured/20101222/our-drug-better-your-drug-id-10145342.html" target="_blank">read more</a></p> http://www.themoneytimes.com/featured/20101222/our-drug-better-your-drug-id-10145342.html#comments approval brand Chance Markets Novartis Onyx Pharmaceuticals positive trial United States Wed, 22 Dec 2010 06:11:40 +0000 Brian Orelli 145342 at http://www.themoneytimes.com Rediff.com Shares Plunged: What You Need to Know http://www.themoneytimes.com/featured/20101204/rediffcom-shares-plunged-what-you-need-know-id-10143958.html <div class="field field-type-text field-field-teaser"> <div class="field-items"> <div class="field-item odd"> <p>&nbsp;<meta http-equiv="content-type" content="text/html; charset=utf-8" /><em style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; font-family: inherit; font-size: 14px; font-style: italic; font-weight: inherit; ">Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.</em></p> <div style="color: rgb(34, 34, 34); font-family: Arial, Helvetica, sans-serif; line-height: 22px; font-size: 20.16px; "><em style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; font-family: inherit; font-size: 14px; font-style: italic; font-weight: inherit; "><br /></em></div> </div> </div> </div> <p><meta http-equiv="content-type" content="text/html; charset=utf-8" /></p> <div class="field field-type-filefield field-field-image"> <div class="field-items"> <div class="field-item odd"> <img src="http://www.themoneytimes.com/files/imagecache/picturethumb/Rediff.com_.jpg" alt="" title="" class="imagecache imagecache-picturethumb imagecache-default imagecache-picturethumb_default" width="180" height="135" /> </div> </div> </div> <p><a href="http://www.themoneytimes.com/featured/20101204/rediffcom-shares-plunged-what-you-need-know-id-10143958.html" target="_blank">read more</a></p> http://www.themoneytimes.com/featured/20101204/rediffcom-shares-plunged-what-you-need-know-id-10143958.html#comments approval drop high Rediff.com shareholders shares stocks Technology trading United States wholesale Sat, 04 Dec 2010 06:54:00 +0000 Anders Bylund 143958 at http://www.themoneytimes.com Whom Will BHP Billiton Court Next? http://www.themoneytimes.com/featured/20101107/whom-will-bhp-billiton-court-next-id-10140738.html <div class="field field-type-text field-field-teaser"> <div class="field-items"> <div class="field-item odd"> <p>&nbsp;If you ask me, the effort by Australian mining giant&nbsp;<strong style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; font-family: inherit; font-size: 14px; font-style: inherit; font-weight: bold; ">BHP Billiton</strong>&nbsp;<span class="ticker" style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; font-family: inherit; font-size: 14px; font-style: inherit; font-weight: inherit; ">(NYSE:&nbsp;BHP)</span>&nbsp;to spend $38.6 billion for Canada's&nbsp;<strong style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; font-family: inherit; font-size: 14px; font-style: inherit; font-weight: bold; ">PotashCorp</strong>&nbsp;<span class="ticker" style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; font-family: inherit; font-size: 14px; font-style: inherit; font-weight: inherit; ">(NYSE:&nbsp;POT)</span>&nbsp;is as dead as a doornail.</p> <div style="color: rgb(34, 34, 34); font-family: Arial, Helvetica, sans-serif; line-height: 22px; font-size: 20.16px; ">&nbsp;</div> </div> </div> </div> <p>&nbsp;When Potash's board reacted with a quick rejection of its&nbsp;opening gambit, BHP "went hostile," appealing directly to the target company's shareholders.</p> <div class="field field-type-filefield field-field-image"> <div class="field-items"> <div class="field-item odd"> <img src="http://www.themoneytimes.com/files/imagecache/picturethumb/BHP%20logo.jpg" alt="" title="" class="imagecache imagecache-picturethumb imagecache-default imagecache-picturethumb_default" width="180" height="114" /> </div> </div> </div> <p><a href="http://www.themoneytimes.com/featured/20101107/whom-will-bhp-billiton-court-next-id-10140738.html" target="_blank">read more</a></p> http://www.themoneytimes.com/featured/20101107/whom-will-bhp-billiton-court-next-id-10140738.html#comments approval BHP Billiton Business Business earning report Economy Equities investing Investing Investing investment Investors Markets Markets REJECTION United States Vale Sun, 07 Nov 2010 06:02:08 +0000 David Lee Smith 140738 at http://www.themoneytimes.com Taseko's Dead End to Prosperity http://www.themoneytimes.com/featured/20101104/taseko039s-dead-end-prosperity-id-10140429.html <div class="field field-type-text field-field-teaser"> <div class="field-items"> <div class="field-item odd"> <p>&nbsp;Well-wishers may tell you to break a leg, but that doesn't prepare you for having your arms lopped off.</p> <div style="color: rgb(34, 34, 34); font-family: Arial, Helvetica, sans-serif; line-height: 22px; font-size: 20.16px; ">&nbsp;</div> </div> </div> </div> <p>&nbsp;<strong style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; font-family: inherit; font-size: 14px; font-style: inherit; font-weight: bold; ">Taseko Mines</strong>&nbsp;<span class="ticker" style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; </p> </span></p><div class="field field-type-filefield field-field-image"> <div class="field-items"> <div class="field-item odd"> <img src="http://www.themoneytimes.com/files/imagecache/picturethumb/Taseko%20Mine.gif" alt="" title="" class="imagecache imagecache-picturethumb imagecache-default imagecache-picturethumb_default" width="180" height="62" /> </div> </div> </div> <p><a href="http://www.themoneytimes.com/featured/20101104/taseko039s-dead-end-prosperity-id-10140429.html" target="_blank">read more</a></p> http://www.themoneytimes.com/featured/20101104/taseko039s-dead-end-prosperity-id-10140429.html#comments approval Business Business Economy Equities final investing Investing Investing investment Investors Markets Markets News Taseko Mines United States Thu, 04 Nov 2010 07:15:09 +0000 Christopher Barker 140429 at http://www.themoneytimes.com FDA clears Cadence's Ofirmev injection for pain and fever http://www.themoneytimes.com/featured/20101103/fda-clears-cadence039s-ofirmev-injection-pain-and-fever-id-10140290.html <div class="field field-type-text field-field-teaser"> <div class="field-items"> <div class="field-item odd"> <p>San Diego based company Cadence Pharmaceuticals Inc. (Nasdaq:CADX) has won the approval of the U.S. Food and Drug Administration (FDA) to market Ofirmev (acetaminophen), its injected drug for pain and fever relief.</p> </div> </div> </div> <div class="field field-type-filefield field-field-image"> <div class="field-items"> <div class="field-item odd"> <img src="http://www.themoneytimes.com/files/imagecache/picturethumb/logostill.jpg" alt="" title="" class="imagecache imagecache-picturethumb imagecache-default imagecache-picturethumb_default" width="180" height="58" /> </div> </div> </div> <p>The new drug is the only in intravenous (IV) formulation of acetaminophen to be cleared in the United States for treatment of moderate to severe pain.</p> <p>Ofirmev will aid patients who cannot tolerate oral pain killers post operation and also provides doctor an alternative to opioid-based pain relievers that can be addictive and cause serious adverse events like chronic constipation.</p> <p>Ted Schroeder, president and CEO of Cadence declared, "The approval of OFIRMEV is a significant milestone for Cadence as we advance our mission to improve the lives of hospitalized adults and children.</p> <div class="field field-type-text field-field-imagecaption"> <div class="field-items"> <div class="field-item odd"> <p>San Diego based company Cadence Pharmaceuticals Inc. (Nasdaq:CADX), has won the approval of the U.S. Food and Drug Administration (FDA) to market Ofirmev (acetaminophen), its injected drug for pain and fever relief.</p> </div> </div> </div> <p><a href="http://www.themoneytimes.com/featured/20101103/fda-clears-cadence039s-ofirmev-injection-pain-and-fever-id-10140290.html" target="_blank">read more</a></p> http://www.themoneytimes.com/featured/20101103/fda-clears-cadence039s-ofirmev-injection-pain-and-fever-id-10140290.html#comments abdominal laparoscopic surgery adults and children approval Cadence Pharmaceuticals Inc. clinical trials FDA Health injection intravenous (IV) formulation of acetaminophen Ofirmev orthopedic surgery pain and fever Top Story treatment of fever. United States Wed, 03 Nov 2010 09:30:35 +0000 Neka Sehgal 140290 at http://www.themoneytimes.com Approval of ReGen Biologics' knee implant was a mistake--FDA http://www.themoneytimes.com/featured/20101015/approval-regen-biologics039-knee-implant-was-mistakefda-id-10131883.html <div class="field field-type-text field-field-teaser"> <div class="field-items"> <div class="field-item odd"> <p>The fast track decision of approving the sale of a ReGen Biologics Inc. (RGBO) knee implant was a mistake, the U.S. Food and Drug Administration has revealed.</p> </div> </div> </div> <div class="field field-type-filefield field-field-image"> <div class="field-items"> <div class="field-item odd"> <img src="http://www.themoneytimes.com/files/imagecache/picturethumb/menaflex-scaffold-F250x250.jpg" alt="" title="" class="imagecache imagecache-picturethumb imagecache-default imagecache-picturethumb_default" width="180" height="127" /> </div> </div> </div> <p>The FDA had in 2008 allowed approved Menaflex Collagen Scaffold despite objections by the FDA scientists who sought more rigorous evaluations.</p> <blockquote><p>The device till date has been implanted in about 50 people in the United States and no safety issues have been reported.</p></blockquote> <p>Besides trying to remove the device from the market, the FDA would also meet ReGen Biologics Inc. of Hackensack, N.J, the manufacturing company, in order to see if there is a process through which they could apply again for approval for the implant.</p> <p><strong>Approval given in 2008</strong></p> <div class="field field-type-text field-field-imagecaption"> <div class="field-items"> <div class="field-item odd"> <p>The approval had been given despite objections by the FDA scientific staff, who believed that the device offered little benefit over existing treatments.</p> </div> </div> </div> <p><a href="http://www.themoneytimes.com/featured/20101015/approval-regen-biologics039-knee-implant-was-mistakefda-id-10131883.html" target="_blank">read more</a></p> http://www.themoneytimes.com/featured/20101015/approval-regen-biologics039-knee-implant-was-mistakefda-id-10131883.html#comments approval decision FDA Health knee implant menaflex Menaflex Collagen Scaffold regen Tissue Top Story United States Fri, 15 Oct 2010 07:55:28 +0000 Neha Gupta 131883 at http://www.themoneytimes.com FDA committee recommends more research on genetically modified salmon http://www.themoneytimes.com/featured/20100921/fda-committee-recommends-more-research-genetically-modified-salmon-id-10129157.htm <div class="field field-type-text field-field-teaser"> <div class="field-items"> <div class="field-item odd"> <p>The U.S. Food and Drug Administration (FDA) advisers began two days of hearings to discuss whether to recommend approval of genetically modified salmon as fit for humans consumption. </p> </div> </div> </div> <div class="field field-type-filefield field-field-image"> <div class="field-items"> <div class="field-item odd"> <img src="http://www.themoneytimes.com/files/imagecache/picturethumb/salmon_genetically_modified.jpg" alt="" title="" class="imagecache imagecache-picturethumb imagecache-default imagecache-picturethumb_default" width="180" height="120" /> </div> </div> </div> <p>If approved, the salmon, developed by AquaBounty Technologies Inc., would become the country's first genetically engineered food animal.</p> <p>The FDA's advisory committee began its two day proceedings to decide if the genetically modified fish is safe for humans to eat. </p> <p>The committee’s conclusions are not binding on the FDA, but it generally listens to its recommendations. </p> <p><strong>Committee in favor of further research</strong><br /> David Senior of Louisiana State University, also president of the Committee, said that </p> <div class="field field-type-text field-field-imagecaption"> <div class="field-items"> <div class="field-item odd"> <p>AquaBounty said it would take at least 18 months to bring the salmon to market after getting FDA approval. </p> </div> </div> </div> <p><a href="http://www.themoneytimes.com/featured/20100921/fda-committee-recommends-more-research-genetically-modified-salmon-id-10129157.htm" target="_blank">read more</a></p> http://www.themoneytimes.com/featured/20100921/fda-committee-recommends-more-research-genetically-modified-salmon-id-10129157.htm#comments approval Aquabounty Technologies consumption FDA Genetically modified Health preliminary findings research salmon Top Story United States Tue, 21 Sep 2010 14:14:39 +0000 Anter Prakash Singh 129157 at http://www.themoneytimes.com
Warning: trigger_error(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /home/themoney/public_html/includes/database.mysql.inc on line 135

Warning: Table './themoney_2011new/watchdog' is marked as crashed and last (automatic?) repair failed query: INSERT INTO watchdog (uid, type, message, variables, severity, link, location, referer, hostname, timestamp) VALUES (0, 'php', '%message in %file on line %line.', 'a:4:{s:6:\"%error\";s:12:\"user warning\";s:8:\"%message\";s:320:\"Table &#039;themoney_2011new.accesslog&#039; doesn&#039;t exist\nquery: INSERT INTO accesslog (title, path, url, hostname, uid, sid, timer, timestamp) values(&#039;&#039;, &#039;taxonomy/term/10362/all/feed&#039;, &#039;&#039;, &#039;54.144.83.141&#039;, 0, &#039;f28301f8b6a756d83181ad6f1241f122&#039;, 1151, 1455422043)\";s:5:\"%file\";s:63:\"/home/themoney/public_html/modules/statistics/statistics.module\";s:5:\"%line\";i:63;}', 3, '', 'http://www.themoneytimes.com/taxonomy/term/10362/all/feed' in /home/themoney/public_html/includes/database.mysql.inc on line 135